Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis

Journal of Hepatology

Volumn 61, Issue 3, 2014, Pages 482-491

  Maan, Raoel ^a   Van Der Meer, Adriaan J ^a   Hansen, Bettina E ^a   Feld, Jordan J ^b   Wedemeyer, Heiner ^c   Dufour, Jean François ^d   Zangneh, Hooman F ^b   Lammert, Frank ^e   Manns, Michael P ^c   Zeuzem, Stefan ^f   Janssen, Harry L A ^a,b   De Knegt, Robert J ^a   Veldt, Bart J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY OF BERN   (Switzerland)

^e SAARLAND UNIVERSITY   (Germany)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Antiviral treatment; Bleeding; Chronic hepatitis c; Complications; Interferon; Side effects

Indexed keywords

INTERFERON; PEGINTERFERON; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CANADA; CONTROLLED STUDY; DEATH; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EPISTAXIS; EUROPE; FEMALE; GINGIVA BLEEDING; HEMATURIA; HEMOPTYSIS; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECTUM HEMORRHAGE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VAGINA BLEEDING; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; HEMORRHAGE; HEPACIVIRUS; HEPATITIS C, CHRONIC; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PHYSIOLOGY; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT WITHDRAWAL; VIRUS REPLICATION;

ADULT; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMORRHAGE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRUS REPLICATION; WITHHOLDING TREATMENT;

EID: 84906327405     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.04.021     Document Type: Article

References (39)

1. T. Poynard, P. Bedossa, and P. Opolon Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups Lancet 349 1997 825 832
2. E. Giannini, P. Borro, F. Botta, A. Fumagalli, F. Malfatti, and E. Podesta et al. Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis J Hepatol 37 2002 572 577
3. M. Olariu, C. Olariu, and D. Olteanu Thrombocytopenia in chronic hepatitis C J Gastrointest Liver Dis 19 2010 381 385
4. P. Pradella, S. Bonetto, S. Turchetto, L. Uxa, C. Comar, and F. Zorat et al. Platelet production and destruction in liver cirrhosis J Hepatol 54 2011 894 900
5. N. Afdhal, J. McHutchison, R. Brown, I. Jacobson, M. Manns, and F. Poordad et al. Thrombocytopenia associated with chronic liver disease J Hepatol 48 2008 1000 1007
6. E.G. Giannini Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options Aliment Pharmacol Ther 23 2006 1055 1065
7. A.C. Cardoso, R. Moucari, C. Figueiredo-Mendes, M.P. Ripault, N. Giuily, and C. Castelnau et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis J Hepatol 52 2010 652 657
8. T.R. Morgan, M.G. Ghany, H.Y. Kim, K.K. Snow, M.L. Shiffman, and J.L. De Santo et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C Hepatology 52 2010 833 844
9. A.J. van der Meer, B.J. Veldt, J.J. Feld, H. Wedemeyer, J.F. Dufour, and F. Lammert et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis JAMA 308 2012 2584 2593
10. E. Vezali, A. Aghemo, and M. Colombo A review of the treatment of chronic hepatitis C virus infection in cirrhosis Clin Ther 32 2010 2117 2138
11. J.G. McHutchison, M. Manns, K. Patel, T. Poynard, K.L. Lindsay, and C. Trepo et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C Gastroenterology 123 2002 1061 1069
12. M.L. Shiffman, M.G. Ghany, T.R. Morgan, E.C. Wright, G.T. Everson, and K.L. Lindsay et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C Gastroenterology 132 2007 103 112
13. B.R. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, and S. Zeuzem et al. Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
14. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, and N.H. Bzowej et al. Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
15. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M.P. Manns, and M.S. Sulkowski et al. Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
16. K.E. Sherman, S.L. Flamm, N.H. Afdhal, D.R. Nelson, M.S. Sulkowski, and G.T. Everson et al. Response-guided telaprevir combination treatment for hepatitis C virus infection N Engl J Med 365 2011 1014 1024
17. S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, and S. Roberts et al. Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
18. C. Hezode, H. Fontaine, C. Dorival, D. Larrey, F. Zoulim, and V. Canva et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890 J Hepatol 59 2013 434 441
19. European Association of the Study of the Liver 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines Liver Int 32 2012 2 8
20. D.B. Strader, T. Wright, D.L. Thomas, and L.B. Seeff American Association for the Study of Liver. Diagnosis, management, and treatment of hepatitis C Hepatology 39 2004 1147 1171
21. A.J. van der Meer, B.J. Veldt, J.J. Feld, H. Wedemeyer, J.F. Dufour, and F. Lammert et al. The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection J Viral Hepat 21 2014 568 577
22. B.J. Veldt, E.J. Heathcote, H. Wedemeyer, J. Reichen, W.P. Hofmann, and S. Zeuzem et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis Ann Intern Med 147 2007 677 684
23. M.F. Buckley, J.W. James, D.E. Brown, G.S. Whyte, M.G. Dean, and C.N. Chesterman et al. A novel approach to the assessment of variations in the human platelet count Thromb Haemost 83 2000 480 484
24. J. Bruix, and M. Sherman Practice Guidelines Committee AAftSoLD. Management of hepatocellular carcinoma Hepatology 42 2005 1208 1236
25. E.G. Giannini, S. Marenco, V. Fazio, G. Pieri, V. Savarino, and A. Picciotto Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy Liver Int 32 2012 1113 1119
26. G.L. Davis, M.J. Alter, H. El-Serag, T. Poynard, and L.W. Jennings Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression Gastroenterology 138 2010 513 521 [e511-e516]
27. E.J. Heathcote, M.L. Shiffman, W.G. Cooksley, G.M. Dusheiko, S.S. Lee, and L. Balart et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis N Engl J Med 343 2000 1673 1680
28. K.H. Lin, P.I. Hsu, H.C. Yu, C.K. Lin, W.L. Tsai, and W.C. Chen et al. Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis c and pretreatment low platelet counts BMC Gastroenterol 12 2012 7
29. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, and F.L. Goncales Jr. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
30. S.J. Hadziyannis, H. Sette Jr., T.R. Morgan, V. Balan, M. Diago, and P. Marcellin et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
31. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, and R. Reindollar et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
32. R. Roomer, B.E. Hansen, H.L. Janssen, and R.J. de Knegt Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C J Hepatol 53 2010 455 459
33. G. Fattovich, G. Giustina, F. Degos, F. Tremolada, G. Diodati, and P. Almasio et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients Gastroenterology 112 1997 463 472
34. B. Maasoumy, and H. Wedemeyer Natural history of acute and chronic hepatitis C Best Pract Res Clin Gastroenterol 26 2012 401 412
35. T. Reiberger, K. Rutter, A. Ferlitsch, B.A. Payer, H. Hofer, and S. Beinhardt et al. Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection Clin Gastroenterol Hepatol 9 2011 e601
36. S.N. Lu, J.H. Wang, S.L. Liu, C.H. Hung, C.H. Chen, and H.D. Tung et al. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma Cancer 107 2006 2212 2222
37. N.H. Afdhal, G.M. Dusheiko, E.G. Giannini, P.J. Chen, K.H. Han, and A. Mohsin et al. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy Gastroenterology 146 442-452 2014 e441
38. N.H. Afdhal, and J.G. McHutchison Review article: pharmacological approaches for the treatment of thrombocytopenia in patients with chronic liver disease and hepatitis C infection Aliment Pharmacol Ther 26 2007 29 39
39. E.G. Giannini, and N.H. Afdhal Eltrombopag in patients with chronic liver disease Expert Opin Pharmacother 14 2013 669 678